153 related articles for article (PubMed ID: 35343818)
1. The Potential of Salivary Lipid-Based Cannabis-Responsive Biomarkers to Evaluate Medical Cannabis Treatment in Children with Autism Spectrum Disorder.
Siani-Rose M; McKee R; Cox S; Goldstein B; Abrams D; Taylor M; Kurek I
Cannabis Cannabinoid Res; 2023 Aug; 8(4):642-656. PubMed ID: 35343818
[No Abstract] [Full Text] [Related]
2. Cannabis-Responsive Biomarkers: A Pharmacometabolomics-Based Application to Evaluate the Impact of Medical Cannabis Treatment on Children with Autism Spectrum Disorder.
Siani-Rose M; Cox S; Goldstein B; Abrams D; Taylor M; Kurek I
Cannabis Cannabinoid Res; 2023 Feb; 8(1):126-137. PubMed ID: 34874191
[No Abstract] [Full Text] [Related]
3. A machine learning approach for understanding the metabolomics response of children with autism spectrum disorder to medical cannabis treatment.
Quillet JC; Siani-Rose M; McKee R; Goldstein B; Taylor M; Kurek I
Sci Rep; 2023 Aug; 13(1):13022. PubMed ID: 37608004
[TBL] [Abstract][Full Text] [Related]
4. Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasibility Study.
Aran A; Cassuto H; Lubotzky A; Wattad N; Hazan E
J Autism Dev Disord; 2019 Mar; 49(3):1284-1288. PubMed ID: 30382443
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with Commonly Used Medications.
Holdman R; Vigil D; Robinson K; Shah P; Contreras AE
Cannabis Cannabinoid Res; 2022 Aug; 7(4):451-463. PubMed ID: 34432543
[No Abstract] [Full Text] [Related]
6. Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy.
Bar-Lev Schleider L; Mechoulam R; Saban N; Meiri G; Novack V
Sci Rep; 2019 Jan; 9(1):200. PubMed ID: 30655581
[TBL] [Abstract][Full Text] [Related]
7. Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder.
Poleg S; Kourieh E; Ruban A; Shapira G; Shomron N; Barak B; Offen D
Transl Psychiatry; 2021 Oct; 11(1):524. PubMed ID: 34645786
[TBL] [Abstract][Full Text] [Related]
8. VLDL-specific increases of fatty acids in autism spectrum disorder correlate with social interaction.
Usui N; Iwata K; Miyachi T; Takagai S; Wakusawa K; Nara T; Tsuchiya KJ; Matsumoto K; Kurita D; Kameno Y; Wakuda T; Takebayashi K; Iwata Y; Fujioka T; Hirai T; Toyoshima M; Ohnishi T; Toyota T; Maekawa M; Yoshikawa T; Maekawa M; Nakamura K; Tsujii M; Sugiyama T; Mori N; Matsuzaki H
EBioMedicine; 2020 Aug; 58():102917. PubMed ID: 32739868
[TBL] [Abstract][Full Text] [Related]
9. Identification of developmental disorders including autism spectrum disorder using salivary miRNAs in children from Bosnia and Herzegovina.
Sehovic E; Spahic L; Smajlovic-Skenderagic L; Pistoljevic N; Dzanko E; Hajdarpasic A
PLoS One; 2020; 15(4):e0232351. PubMed ID: 32353026
[TBL] [Abstract][Full Text] [Related]
10. Metabolomics as a tool for discovery of biomarkers of autism spectrum disorder in the blood plasma of children.
West PR; Amaral DG; Bais P; Smith AM; Egnash LA; Ross ME; Palmer JA; Fontaine BR; Conard KR; Corbett BA; Cezar GG; Donley EL; Burrier RE
PLoS One; 2014; 9(11):e112445. PubMed ID: 25380056
[TBL] [Abstract][Full Text] [Related]
11. Autism Spectrum Disorder and Medical Cannabis: Review and Clinical Experience.
Mostafavi M; Gaitanis J
Semin Pediatr Neurol; 2020 Oct; 35():100833. PubMed ID: 32892960
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid treatment for the symptoms of autism spectrum disorder.
Aran A; Cayam Rand D
Expert Opin Emerg Drugs; 2024 Mar; 29(1):65-79. PubMed ID: 38226593
[TBL] [Abstract][Full Text] [Related]
13. CBD-enriched cannabis for autism spectrum disorder: an experience of a single center in Turkey and reviews of the literature.
Bilge S; Ekici B
J Cannabis Res; 2021 Dec; 3(1):53. PubMed ID: 34911567
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial.
Silva EAD; Medeiros WMB; Santos JPMD; Sousa JMM; Costa FBD; Pontes KM; Borges TC; Espínola C; Andrade E Silva AH; Nunes ELG; Alves NT; Rosa MDD; Albuquerque KLGD
Trends Psychiatry Psychother; 2024; 46():e20210396. PubMed ID: 35617670
[TBL] [Abstract][Full Text] [Related]
15.
Correia BSB; de Moraes Pontes JG; Nani JVS; Villalta F; Mor NC; Bordini D; Brunoni D; Brentani H; Mari JJ; Hayashi MAF; Tasic L
ACS Chem Neurosci; 2023 Mar; 14(6):1137-1145. PubMed ID: 36808953
[TBL] [Abstract][Full Text] [Related]
16. A Proteomics Investigation of Salivary Profiles as Potential Biomarkers for Autism Spectrum Disorder (ASD).
Wormwood KL; Charette L; Ryan JP; Darie CC; Woods AG
Protein J; 2023 Oct; 42(5):607-620. PubMed ID: 37566278
[TBL] [Abstract][Full Text] [Related]
17. Salivary miRNA profiles identify children with autism spectrum disorder, correlate with adaptive behavior, and implicate ASD candidate genes involved in neurodevelopment.
Hicks SD; Ignacio C; Gentile K; Middleton FA
BMC Pediatr; 2016 Apr; 16():52. PubMed ID: 27105825
[TBL] [Abstract][Full Text] [Related]
18. Metabolic profiling in children with autism spectrum disorder with and without mental regression: preliminary results from a cross-sectional case-control study.
Rangel-Huerta OD; Gomez-Fernández A; de la Torre-Aguilar MJ; Gil A; Perez-Navero JL; Flores-Rojas K; Martín-Borreguero P; Gil-Campos M
Metabolomics; 2019 Jun; 15(7):99. PubMed ID: 31250215
[TBL] [Abstract][Full Text] [Related]
19. Distinct Fecal and Plasma Metabolites in Children with Autism Spectrum Disorders and Their Modulation after Microbiota Transfer Therapy.
Kang DW; Adams JB; Vargason T; Santiago M; Hahn J; Krajmalnik-Brown R
mSphere; 2020 Oct; 5(5):. PubMed ID: 33087514
[TBL] [Abstract][Full Text] [Related]
20. The Role of Lipidomics in Autism Spectrum Disorder.
El-Ansary A; Chirumbolo S; Bhat RS; Dadar M; Ibrahim EM; Bjørklund G
Mol Diagn Ther; 2020 Feb; 24(1):31-48. PubMed ID: 31691195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]